Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | IL1RN | P18510 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.67 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001537 | 1.00 | MAPT (0.97) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL30213397 | 1.00 | MAPT (0.97) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL1001486 | 0.98 | MAPT (1.00) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL29463849 | 0.98 | MAPT (1.00) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL3932198 | 0.95 | MAPT (0.94) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL19002726 | 0.86 | SMN1; SMN2 (0.75) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL14507610 | 0.86 | GAA (1.00) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL19002721 | 0.86 | SMN1; SMN2 (0.75) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL17911174 | 0.86 | MAPT (0.78) | MAPTIL1RNSMN1; SMN2HTTLMNA | |
| SCHEMBL3824747 | 0.85 | MAPT (0.76) | MAPTIL1RNLMNAGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890117-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170050926-A1 | Benzamide Compounds and Related Methods of Use | NORTHWESTERN UNIVERSITY | 2017-02-23 | — | — | US | disclosed |
| US-20170050926-A1 | Benzamide Compounds and Related Methods of Use | NORTHWESTERN UNIVERSITY | 2017-02-23 | — | — | US | disclosed |
| US-9533947-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2017-01-03 | — | — | US | disclosed |
| US-9371277-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371277-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150025235-A1 | Benzamide Compounds and Related Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-22 | — | — | US | disclosed |
| US-20140234939-A1 | Benzamide Compounds and Related Methods of Use | NORTHWESTERN UNIVERSITY (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234939-A1 | Benzamide Compounds and Related Methods of Use | NORTHWESTERN UNIVERSITY (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014100833-A1 | BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100833-A1 | BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050926-A1 | Benzamide Compounds and Related Methods of Use | SIRT2, SIRT1, SIRT3 | MAPT 248/4885IL1RN 3583/4885SMN1; SMN2 245/4885 |
| US-20140234939-A1 | Benzamide Compounds and Related Methods of Use | SIRT2, SIRT1, SIRT3 | MAPT 248/4885IL1RN 3583/4885SMN1; SMN2 245/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MAPT 759/4885IL1RN 2395/4885SMN1; SMN2 155/4885 |
| US-20150025235-A1 | Benzamide Compounds and Related Methods of Use | SIRT2, SIRT1, SIRT3 | MAPT 248/4885IL1RN 3583/4885SMN1; SMN2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.